Public Law 115-52: FDA Reauthorization Act of 2017

By | October 18, 2017
FDA logo

Food and Drug Administration logo.

Reauthorizes the Federal Food, Drug, and Cosmetic Act through FY2022, with changes to FDA user fees for prescription drugs, medical devices, generic drugs and biosimilars (biological products similar to ones already approved).

Official Summary

Passed House
(amended) 2017-07-12
Passed Senate
2017-08-03
Signed by President
2017-08-18
Became Public Law
2017-08-18

Amendments

Senate amendments: https://www.congress.gov/amendment/115th-congress/senate-amendment/755/text

Sponsors

Original sponsor: Rep. Walden, Greg [R-OR-2]

Cosponsors: Rep. Pallone, Frank, Jr. [D-NJ-6], Rep. Burgess, Michael C. [R-TX-26], Rep. Green, Gene [D-TX-29]

Votes

Passed House by voice vote.

Passed Senate: http://www.senate.gov/legislative/LIS/roll_call_lists/roll_call_vote_cfm.cfm?&congress=115&session=1&vote=00187

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.